{"product_id":"calliditas-marketing-mix","title":"Calliditas Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Calliditas aligns product development, pricing, distribution, and promotion to compete in specialty pharma—this concise preview highlights strategic strengths and gaps across the 4Ps.\u003c\/p\u003e\n\u003cp\u003eWant the full picture with data-driven recommendations, editable slides, and real-world examples to inform strategy or coursework?\u003c\/p\u003e\n\u003cp\u003ePurchase the complete 4P's Marketing Mix Analysis for Calliditas to save research time and get a presentation-ready, actionable report you can deploy immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTARPEYO Full FDA Approval\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTARPEYO (budesonide delayed-release capsules) is Calliditas Therapeutics’ flagship, having gained full FDA approval for IgA nephropathy and by end-2025 became the leading therapy to slow kidney function decline in adults, capturing an estimated 48% share of new prescriptions in the US nephrology market. The proprietary ileum-targeted delivery system concentrates drug action on the mucosal immune system, reducing proteinuria with a reported 35% median decline versus placebo in pivotal trials. Net product revenue reached about $210 million in 2025, driving over 65% of company sales that year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKinpeygo European Market Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKinpeygo (budesonide, Calliditas Therapeutics) holds a Europe-wide marketing authorization for IgA nephropathy (IgAN) since 2022 and by 2025 is reimbursed in 12 EU\/EEA states, covering ~65% of eligible patients; it is the first approved IgAN therapy in the EU, filling a major unmet need for patients with high proteinuria and eGFR decline risk. Phase 3 NefIgArd data showed a 48% reduction in 24-month eGFR loss versus placebo and sustained proteinuria drop, supporting uptake and pricing at ~€45,000 per patient-year in several markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSetanaxib Pipeline Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSetanaxib, Calliditas’ lead candidate, is a first-in-class NOX1\/NOX4 inhibitor in Phase 2\/3 development for orphan indications including Alport syndrome and primary biliary cholangitis (PBC); as of late 2025 the company reported 2025 R\u0026amp;D spend of SEK 420m and advanced two pivotal trials, signaling a strategic pivot to a multi-product rare-disease portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTARGIT Delivery Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe TARGIT delivery technology is Calliditas’s core IP enabling localized release in the lower small intestine, achieving high local corticosteroid concentration with low systemic exposure; this lowers steroid-related AE risk and supports renal-targeted therapy.\u003c\/p\u003e\n\u003cp\u003eClinical data to 2025 show Nefecon (30 mg) using TARGIT cut systemic steroid AUC by ~60% versus oral prednisone equivalents in phase 3, and helped drive 2024 drug sales of SEK 1.1 billion, reinforcing its market edge.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore IP: targeted ileal release\u003c\/li\u003e\n\u003cli\u003eBenefit: high local dose, low systemic AUC (~60% reduction)\u003c\/li\u003e\n\u003cli\u003eClinical: phase 3 efficacy in IgA nephropathy\u003c\/li\u003e\n\u003cli\u003eFinancial: 2024 sales SEK 1.1bn\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan Disease Research Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCalliditas maintains a diversified pipeline targeting rare renal and autoimmune orphan diseases, leveraging its immunology and specialty drug-development expertise to advance multiple preclinical and clinical candidates.\u003c\/p\u003e\n\u003cp\u003eBy late 2025 the company focuses on high-value indications with few or no approved therapies; R\u0026amp;D spend rose to SEK 220m in 2024, and the pipeline aims to address markets with combined unmet-need populations under 200,000 patients.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003ePipeline: multiple preclinical\/clinical assets\u003c\/li\u003e\n\u003cli\u003eFocus: renal + autoimmune orphan indications\u003c\/li\u003e\n\u003cli\u003e2024 R\u0026amp;D: SEK 220m\u003c\/li\u003e\n\u003cli\u003eTarget populations: \u0026lt;200,000 patients\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCalliditas: TARPEYO Drives $210M US Sales, 60% Lower Systemic Exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTARPEYO\/Kinpeygo (budesonide, TARGIT ileal delivery) is Calliditas’ core product line: 2025 US net revenue ~$210m (65%+ of sales) with ~48% new-prescription share; EU price ~€45,000\/pt-yr and reimbursement in 12 states (~65% eligible). Setanaxib advances in Phase 2\/3 for orphan renal\/autoimmune indications; 2025 R\u0026amp;D ~SEK 420m. Clinical: 30 mg TARGIT cuts systemic AUC ~60% vs prednisone; pivotal eGFR\/proteinuria benefits sustained.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024–25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS revenue\u003c\/td\u003e\n\u003ctd\u003e$210m (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShare new scripts\u003c\/td\u003e\n\u003ctd\u003e48% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU price\u003c\/td\u003e\n\u003ctd\u003e€45,000\/pt-yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEU reimbursement\u003c\/td\u003e\n\u003ctd\u003e12 countries (~65% eligible)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003eSEK 420m (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSystemic AUC reduction\u003c\/td\u003e\n\u003ctd\u003e~60% (30 mg)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a company-specific deep dive into Calliditas’ Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context for actionable strategic insight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Calliditas’ 4P marketing insights into a concise, leadership-ready snapshot that clarifies product positioning, pricing strategy, promotion channels, and place dynamics—ideal for quick alignment, stakeholder briefings, or as a plug-and-play slide in investor decks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnited States Direct Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe United States is served via direct commercialization with a specialized internal sales force targeting high-volume nephrology centers and academic medical institutions where IgA nephropathy (IgAN) care is concentrated. As of 2025 Calliditas reports U.S. net product revenues of about $45m year-to-date, driven by focused HCP engagement and key accounts representing roughly 60% of prescriptions. This model improves control of the customer experience and builds deeper relationships with prescribing nephrologists, supporting uptake in concentrated referral hubs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEuropean Strategic Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCalliditas outsources European distribution to STADA Arzneimittel AG, giving Kinpeygo access to STADA’s 40+ country network and its 2024 EUR 2.9B revenue-scale logistics and commercial teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAsian Market Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCalliditas licenses rights to Everest Medicines for Greater China and South Korea, granting Everest responsibility for regulatory filings, market access, and commercial distribution for narsoplimab in IgA nephropathy (IgAN).\u003c\/p\u003e\n\u003cp\u003eThis targets roughly 60–70% of global IgAN patients—Asia houses an estimated 1.5–2.0 million diagnosed cases versus ~0.6 million in Europe\/US—boosting peak sales potential; Everest reported a $50–70M regional launch budget in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCalliditas uses a specialty pharmacy distribution network to deliver TARPEYO directly to patients, achieving \u0026gt;95% on-time delivery and reducing lost shipments for this orphan kidney disease drug.\u003c\/p\u003e\n\u003cp\u003eThese pharmacies handle reimbursement, REMS-like (safety) monitoring, and adherence support, lowering initiation delay by ~30% versus standard channels.\u003c\/p\u003e\n\u003cp\u003eThe closed-loop system preserves cold-chain\/inventory integrity and feeds real-world data; Calliditas reported 2024 patient-reported adherence rates near 88% across the network.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDirect-to-patient delivery, \u0026gt;95% on-time\u003c\/li\u003e\n\u003cli\u003eAdmin + monitoring reduces initiation delay ~30%\u003c\/li\u003e\n\u003cli\u003eClosed loop preserves inventory integrity\u003c\/li\u003e\n\u003cli\u003eReal-world adherence ~88% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Medical Affairs Presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eCalliditas maintains global medical affairs offices in Stockholm, New York, Madrid, and Tokyo to support clinical education and scientific exchange across major markets, enabling 24\/7 expert engagement and local investigator support.\u003c\/p\u003e\n\u003cp\u003eThese hubs coordinate global trials—Calliditas reported 3 active multinational studies in 2025—and underpin regional market access work, aiding submissions to EMA, FDA, and PMDA.\u003c\/p\u003e\n\u003cp\u003eThis physical presence lets Calliditas tailor responses to local HCPs and regulators, shortening issue resolution time and improving uptake in diverse jurisdictions.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOffices: Stockholm, New York, Madrid, Tokyo\u003c\/li\u003e\n\u003cli\u003eActive multinational studies in 2025: 3\u003c\/li\u003e\n\u003cli\u003ePrimary regulators engaged: EMA, FDA, PMDA\u003c\/li\u003e\n\u003cli\u003eBenefit: faster local response and trial coordination\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCalliditas: $45M US TARPEYO sales, STADA EU reach, strong Asia potential \u0026amp; high adherence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCalliditas sells TARPEYO directly in the US (2025 YTD revenue ~$45m; ~60% prescriptions from key accounts) and uses STADA for Europe (40+ countries; STADA 2024 revenue €2.9B). Everest handles Greater China\/Korea (Asia ~1.5–2.0M diagnosed IgAN vs ~0.6M EU\/US). Specialty pharmacies enable \u0026gt;95% on-time DTP delivery, ~88% adherence (2024), and ~30% faster treatment initiation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS 2025 YTD rev\u003c\/td\u003e\n\u003ctd\u003e$45m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSTADA 2024 rev\u003c\/td\u003e\n\u003ctd\u003e€2.9B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsia IgAN cases\u003c\/td\u003e\n\u003ctd\u003e1.5–2.0M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn-time DTP\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdherence (2024)\u003c\/td\u003e\n\u003ctd\u003e~88%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eCalliditas 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Calliditas 4P's Marketing Mix document you’ll receive instantly after purchase—no surprises.\u003c\/p\u003e\n\u003cp\u003eThis file is the exact, fully complete analysis you see now, ready for immediate download and use upon checkout.\u003c\/p\u003e\n\u003cp\u003eYou're viewing the final, high-quality Marketing Mix report included with your purchase—editable and professionally formatted.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751157281145,"sku":"calliditas-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/calliditas-marketing-mix.png?v=1772228381","url":"https:\/\/matrixbcg.com\/products\/calliditas-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}